MA27753A1 - Nouvelle diphénylazétidinone ayant des caractéristiques physiologiques améliorées, son procédé de production, médicaments contenant ledit composé et utilisation de ce dernier - Google Patents

Nouvelle diphénylazétidinone ayant des caractéristiques physiologiques améliorées, son procédé de production, médicaments contenant ledit composé et utilisation de ce dernier

Info

Publication number
MA27753A1
MA27753A1 MA28529A MA28529A MA27753A1 MA 27753 A1 MA27753 A1 MA 27753A1 MA 28529 A MA28529 A MA 28529A MA 28529 A MA28529 A MA 28529A MA 27753 A1 MA27753 A1 MA 27753A1
Authority
MA
Morocco
Prior art keywords
compound
diphenylazetidinone
novel
producing
same
Prior art date
Application number
MA28529A
Other languages
English (en)
Inventor
Gerhard Jaehne
Wendelin Frick
Andreas Lindenschmidt
Stefanie Flohr
Hubert Heuer
Hans-Ludwig Schaefer
Werner Kramer
Eric Galia
Heiner Glombik
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MA27753A1 publication Critical patent/MA27753A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention concerne un nouveau diphénylazétidinone, un procédé de production associé, un médicament contenant ledit composé et leurs utilisations. L'invention concerne également le composé de formule (I) ainsi que ses sels physiologiquement acceptables. Le composé est utilisé par exemple en tant qu'agent hypolipidémique.
MA28529A 2003-04-01 2005-09-30 Nouvelle diphénylazétidinone ayant des caractéristiques physiologiques améliorées, son procédé de production, médicaments contenant ledit composé et utilisation de ce dernier MA27753A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10314610A DE10314610A1 (de) 2003-04-01 2003-04-01 Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung

Publications (1)

Publication Number Publication Date
MA27753A1 true MA27753A1 (fr) 2006-02-01

Family

ID=33103147

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28529A MA27753A1 (fr) 2003-04-01 2005-09-30 Nouvelle diphénylazétidinone ayant des caractéristiques physiologiques améliorées, son procédé de production, médicaments contenant ledit composé et utilisation de ce dernier

Country Status (43)

Country Link
US (2) US7205290B2 (fr)
EP (2) EP1613589B1 (fr)
JP (1) JP2006522040A (fr)
KR (1) KR20050119180A (fr)
CN (2) CN100361970C (fr)
AR (1) AR043783A1 (fr)
AT (2) ATE423766T1 (fr)
AU (1) AU2004226287B2 (fr)
BR (1) BRPI0408920A (fr)
CA (1) CA2520689A1 (fr)
CL (1) CL43489B (fr)
CR (1) CR7995A (fr)
CY (2) CY1107398T1 (fr)
DE (3) DE10314610A1 (fr)
DK (2) DK1862455T3 (fr)
EC (1) ECSP056071A (fr)
ES (2) ES2298731T3 (fr)
GT (1) GT200400058A (fr)
HN (1) HN2004000109A (fr)
HR (1) HRP20050870A2 (fr)
JO (1) JO2493B1 (fr)
MA (1) MA27753A1 (fr)
ME (1) MEP41408A (fr)
MX (1) MXPA05010128A (fr)
MY (1) MY136269A (fr)
NI (1) NI200500164A (fr)
NO (1) NO20055001L (fr)
NZ (1) NZ542751A (fr)
PA (1) PA8599401A1 (fr)
PE (1) PE20050011A1 (fr)
PL (2) PL1613589T3 (fr)
PT (2) PT1862455E (fr)
RS (1) RS51146B (fr)
RU (1) RU2334737C2 (fr)
SA (1) SA04250154B1 (fr)
SI (2) SI1862455T1 (fr)
SV (1) SV2004001756A (fr)
TN (1) TNSN05244A1 (fr)
TW (1) TW200504009A (fr)
UA (1) UA80754C2 (fr)
UY (1) UY28253A1 (fr)
WO (1) WO2004087655A1 (fr)
ZA (1) ZA200506708B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20030498A2 (en) * 2000-12-21 2005-04-30 Aventis Pharma Deutschland Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
DE602006010870D1 (de) 2005-06-20 2010-01-14 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
US7067689B1 (en) 2005-07-08 2006-06-27 Microbia, Inc. Process for production of pentahydroxyhexylcarbamoyl alkanoic acids
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
US20080319221A1 (en) * 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
DE102007029612A1 (de) * 2007-06-27 2009-01-08 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Pentahydroxyhexylcarbamoylundekan- säurebenzylester
US20080319218A1 (en) * 2007-06-22 2008-12-25 Andreas Haubrich Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
DE102007054497B3 (de) * 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
EA018974B9 (ru) * 2008-02-05 2014-04-30 Харбор Терапьютикс, Инк. Твердые лекарственные формы
DE102008059772A1 (de) 2008-12-01 2010-06-02 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung eines Diphenylazetidinons
WO2009112203A1 (fr) * 2008-03-14 2009-09-17 Sanofi-Aventis Deutschland Gmbh Procédé de fabrication d’une diphénylazétidinone
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2011157827A1 (fr) 2010-06-18 2011-12-22 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
EP2683702B1 (fr) 2011-03-08 2014-12-24 Sanofi Nouveaux dérivés de phényle-oxathiazine substitués, leur procédé de fabrication, médicament contenant ces liaisons et son utilisation
EP2683701B1 (fr) 2011-03-08 2014-12-24 Sanofi Dérivés d'oxathiazine substitués par des groupes de benzyle-méthyles ou d'hétéro-méthyles, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683705B1 (fr) 2011-03-08 2015-04-22 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
EP2683699B1 (fr) 2011-03-08 2015-06-24 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683698B1 (fr) 2011-03-08 2017-10-04 Sanofi Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
US10426480B2 (en) * 2015-04-29 2019-10-01 Covidien Lp Cutting ring assembly with rigid cutting member

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US576470A (en) * 1897-02-02 Boiler-furnace
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5756740A (en) * 1992-04-08 1998-05-26 Eastman Kodak Company Process for the preparation of binary sensitizing dyes
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
AU727775B2 (en) 1996-01-17 2000-12-21 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
PL338013A1 (en) 1997-07-16 2000-09-25 Novo Nordisk As Derivatives of condensed 1,2,4-thiadiazine, their production and application
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
WO1999046262A1 (fr) 1998-03-12 1999-09-16 Teijin Limited Derives de benzofurylpyrone
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
DE69922043T2 (de) 1998-12-07 2005-11-24 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Glp-1 analoge
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
EP1177176B1 (fr) 1999-04-28 2006-04-19 Aventis Pharma Deutschland GmbH Derives d'acide tri-aryle en tant que ligands pour recepteur de peroxisome a activation par proliferateur (ppar)
NZ515086A (en) 1999-04-28 2003-10-31 Aventis Pharma Gmbh Di-aryl acid derivatives as PPAR receptor ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
DE60029446T2 (de) 1999-06-18 2007-02-08 Merck & Co., Inc. Arylthiazolidindione und aryloxazolidindion-derivate
EP1076066A1 (fr) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides abaissant le taux de glucose sanguin
BR0012752A (pt) 1999-07-29 2002-04-02 Lilly Co Eli Benzofuril piperazinas e benzofuril homopiperazinas: agonistas de serotonina
HUP0202472A3 (en) 1999-09-01 2005-03-29 Aventis Pharma Gmbh Sulfonyl carboxiamide derivatives, method for their production and their use as medicaments
WO2001062266A2 (fr) 2000-02-25 2001-08-30 Novo Nordisk A/S Inhibition de la degenerescence des cellules beta
AU5257401A (en) 2000-04-28 2001-11-12 Asahi Chemical Ind Novel bicyclic compounds
DE60115227T2 (de) 2000-05-11 2006-08-24 Bristol-Myers Squibb Co. Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
HUP0004741A2 (hu) 2000-11-28 2002-12-28 Sanofi-Synthelabo Kémiai eljárás tiazolszármazékok előállítására és új intermedier
HRP20030498A2 (en) * 2000-12-21 2005-04-30 Aventis Pharma Deutschland Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
DE10139416A1 (de) 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
HRP20040199A2 (en) 2001-08-31 2005-04-30 Aventis Pharma Deutschland Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
US6884812B2 (en) 2001-08-31 2005-04-26 Aventis Pharma Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
US7176194B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
BRPI0408920A (pt) 2006-03-28
DE502004009059D1 (de) 2009-04-09
PA8599401A1 (es) 2004-10-08
KR20050119180A (ko) 2005-12-20
EP1613589B1 (fr) 2008-02-13
PT1862455E (pt) 2009-04-23
NO20055001L (no) 2005-10-27
SV2004001756A (es) 2004-11-18
US20070197498A1 (en) 2007-08-23
CN100361970C (zh) 2008-01-16
EP1862455A2 (fr) 2007-12-05
CY1107398T1 (el) 2012-12-19
HN2004000109A (es) 2008-02-21
RS51146B (sr) 2010-10-31
US7205290B2 (en) 2007-04-17
CN101139306A (zh) 2008-03-12
GT200400058A (es) 2004-11-10
HRP20050870A2 (en) 2006-10-31
NI200500164A (es) 2006-01-11
SI1613589T1 (sl) 2008-06-30
DK1862455T3 (da) 2009-06-02
ATE386020T1 (de) 2008-03-15
UY28253A1 (es) 2004-11-08
PL1862455T3 (pl) 2009-07-31
EP1862455B1 (fr) 2009-02-25
CN1768034A (zh) 2006-05-03
RU2334737C2 (ru) 2008-09-27
CY1109055T1 (el) 2014-07-02
PE20050011A1 (es) 2005-02-28
CR7995A (es) 2006-09-22
US7772429B2 (en) 2010-08-10
ES2322876T3 (es) 2009-06-30
AR043783A1 (es) 2005-08-10
EP1862455A3 (fr) 2007-12-12
WO2004087655A1 (fr) 2004-10-14
ECSP056071A (es) 2006-01-27
CL43489B (es) 2005-01-21
SA04250154B1 (ar) 2007-10-29
RU2005133631A (ru) 2006-03-10
DK1613589T3 (da) 2008-06-09
HK1087697A1 (zh) 2006-10-20
UA80754C2 (en) 2007-10-25
NZ542751A (en) 2007-05-31
PT1613589E (pt) 2008-03-27
MEP41408A (en) 2011-02-10
ES2298731T3 (es) 2008-05-16
TNSN05244A1 (en) 2007-06-11
RS20050719A (sr) 2008-04-04
ZA200506708B (en) 2007-01-31
MXPA05010128A (es) 2005-11-16
DE502004006195D1 (de) 2008-03-27
ATE423766T1 (de) 2009-03-15
EP1613589A1 (fr) 2006-01-11
PL1613589T3 (pl) 2008-07-31
JO2493B1 (en) 2009-10-05
AU2004226287B2 (en) 2010-03-18
US20050020563A1 (en) 2005-01-27
CA2520689A1 (fr) 2004-10-14
MY136269A (en) 2008-09-30
DE10314610A1 (de) 2004-11-04
JP2006522040A (ja) 2006-09-28
TW200504009A (en) 2005-02-01
SI1862455T1 (sl) 2009-06-30
AU2004226287A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
MA27753A1 (fr) Nouvelle diphénylazétidinone ayant des caractéristiques physiologiques améliorées, son procédé de production, médicaments contenant ledit composé et utilisation de ce dernier
MX2022013637A (es) Nuevos compuestos de triazinoindol.
MA29620B1 (fr) Nouveau derive de 1,4-benzothiazepine-1,1-dioxyde presentant des proprietes ameliorees, procede pour sa preparation, medicaments contenant ce compose, et son utilisation
MA27697A1 (fr) Derive de phenethanolamine utilise dans le traitement des maladies respiratoires
EA200600223A1 (ru) Замещённый 2-аминотетралины для лечения депрессии
ES2153031T3 (es) Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf.
MA29311B1 (fr) Derives d'isoxazolines et son nouveau procede de production
MXPA04006033A (es) Dicetopiperacinas sustituidas como antagonistas de oxitocina.
RU94044454A (ru) Ингибитор аутоимунных заболеваний
AU2003249575A1 (en) A process for preparing pharmaceutical compositions containing 4-aminoquinolines compounds for treatment of inflammatory disorders of the eye and compositions resulting therefrom
RU94044356A (ru) Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с
NO20034526D0 (no) Nye fremgangsmåter for fremstilling av oksabispiner
EP4685142A8 (fr) Composé triazine et son utilisation
ATE184793T1 (de) Die verwendung von carbostyrilderivaten zur herstellung eines arzneimittels zur hemmung der produktion von interleukin-8
KR960031442A (ko) 페닐시클로헥실카르복스아미드의 용도
ATE267832T1 (de) Substanz gm-95, verfahren zu ihrer herstellung und ihre verwendung
SE9802546D0 (sv) Medicinal product and method for treatment and prevention of dyskinesia
EA200401011A1 (ru) Новые соединения аминокислоты, способ их получения и фармацевтические композиции, содержащие их
PT1317427E (pt) Processo para a producao de compostos quirais
EA200401432A1 (ru) Сложноэфирные производные декагидроизохинолин-3-карбоновой кислоты в качестве анальгетиков
TW200502204A (en) Oligo acid derivatives
EA200400709A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
MY143280A (en) Method of treating inflammatory disease with cardamonin
SE0201881D0 (sv) Novel compounds, their use, and preparation
KR20030004468A (ko) 안압을 저하시키는 티몰롤의 효과를 연장하는 방법